ArticleActa pharmaceutica Sinica. B2022
A polyphenol-assisted IL-10 mRNA delivery system for ulcerative colitis.
Article in Acta pharmaceutica Sinica. B, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 47 citations in OpenAlex.
- Modular design for drug delivery across hierarchical gastrointestinal barriers: From materials to systems.Materials today. Bio · 2026Review
- Targeted intracellular oral RNA delivery through tea polyphenol nanovesicle to outer membrane vesicle transfer for colitis treatment.Science advances · 2026Article
- Improved efficacy and long-term protective effects of CXCR4/IL10 bioengineered mesenchymal stromal cells in a model of inflammatory bowel disease.Bioengineering & translational medicine · 2026Article
- The mRNA-Based Innovative Strategy: Progress and Challenges.Nano-micro letters · 2026Review
- Modulation of distinct gut microbiota signatures in acute and chronic DSS-colitis by Bawei Huangqin enema in mice.iScience · 2025Article
- Anti-migratory Properties of Cryoprotective Isoliquiritigenin-zein Phosphatidylcholine Nanoparticles Prevent Triple-negative Breast Cancer through PI3K-mTOR and MMP2/9 Pathways.Current medicinal chemistry · 2025Article
- Annexin A1 and A2 in inflammatory bowel disease pathogenesis: exploring new avenues for diagnosis and treatment.Frontiers in immunology · 2025Review
- Progress and prospects of mRNA-based drugs in pre-clinical and clinical applications.Signal transduction and targeted therapy · 2024Review
- Layer by layer self-assembled hyaluronic acid nanoarmor for the treatment of ulcerative colitis.Journal of nanobiotechnology · 2024Article
- Enzyme/ROS dual-sensitive nanoplatform with on-demand Celastrol release capacity for enhanced ulcerative colitis therapy by ROS scavenging, microbiota rebalancing, inflammation alleviating.Journal of nanobiotechnology · 2024Article
- Leveraging high-throughput screening technologies in targeted mRNA delivery.Materials today. Bio · 2024Review
- Michael Acceptors as Anti-Cancer Compounds: Coincidence or Causality?International journal of molecular sciences · 2024Review
- Antioxidant Metabolism Pathways in Vitamins, Polyphenols, and Selenium: Parallels and Divergences.International journal of molecular sciences · 2024Review
- Hyaluronic Acid-Mediated Phenolic Compound Nanodelivery for Cancer Therapy.Pharmaceutics · 2023Review
- Engineering polyphenol-based carriers for nucleic acid delivery.Theranostics · 2023Review
- Nanotechnology-based mRNA vaccines.Nature reviews. Methods primers · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
With the development of synthesis technology, modified messenger RNA (mRNA) has emerged as a novel category of therapeutic agents for a broad of diseases. However, effective intracellular delivery of mRNA remains challenging, especially for its sensitivity to enzymatic degradation. Here, we propose a polyphenol-assisted handy delivery strategy for efficient
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.